At the recent International Conference on Alzheimer’s and Parkinson’s Diseases in Gothenburg, Sweden, researchers discussed how they might hone antibodies and vaccination strategies to become ...

Antibodies have proven to be an excellent ... The future of all small single domains is clearly to provide new binding specificities, particularly to targets inaccessible to conventional antigen ...

These antibodies recognize targets using a single, small protein domain called a nanobody, also known as a VHH domain. Vaccination of these mice using proteins based on the SARS-CoV-2 spike ...

Originally derived from camelid heavy chain antibodies, single domain or VHH antibodies can bind epitopes that are inaccessible to conventional monoclonal antibodies due to their small size. Because ...

Allen Guo, CEO "We are excited to present our pre-clinical findings at the AACR, showcasing the significant potential of our CD3 agonistic single-domain antibody," said Allen Guo, CEO.

Single domain antibodies (AKA nanobodies), the variable domains of some camelid antibodies, have interesting properties, including high production yields and stability but also the ability to bind ...

Single-domain antibodies, or nanobodies, have recently been thrust into the spotlight as a potential treatment for COVID-19. In fact, a COVID-19 nanobody-based treatment developed by the Beroni ...

Valour Bio has been established as a wholly owned subsidiary of Valerio Therapeutics to focus on discovering single domain antibodies (sdAbs) as drug and radio conjugates, bispecific T-cell ...

The antibody therapeutics industry is growing at an incredible pace. From early monoclonal therapeutic antibodies to modern bispecific and multispecific antibodies, single domain antibodies (VHHs ...